Onelar 30 mg tvrde želučanootporne

Glavna informacija

  • Trgovački naziv:
  • Onelar 30 mg tvrde želučanootporne kapsule
  • Doziranje:
  • 30 mg
  • Farmaceutski oblik:
  • želučanootporna kapsula, tvrda
  • Sastav:
  • Urbroj: jedna kapsula sadrži 30 mg duloksetina (u obliku klorida)
  • Tip recepta:
  • na recept, u ljekarni ponovljivi recept
  • Koristi za:
  • Ljudi
  • Vrsta lijekova:
  • alopatski lijek
  • Proizveden od:
  • Medochemie Ltd., Limassol, Cipar

Dokument

Lokalizacija

  • Na raspolaganju u:
  • Onelar 30 mg tvrde želučanootporne kapsule
    Hrvatska
  • Jezik:
  • hrvatski

Terapeutski informacija

  • Proizvod sažetak:
  • Pakiranje: 7 kapsula u blisteru, u kutiji [HR-H-879151074-01]; 28 kapsula u blisteru, u kutiji [HR-H-879151074-02]; 30 kapsula u blisteru, u kutiji [HR-H-879151074-03]; 56 kapsula u blisteru, u kutiji [HR-H-879151074-04]; 84 kapsule u blisteru, u kutiji [HR-H-879151074-05]; 98 kapsula u blisteru, u kutiji [HR-H-879151074-06]; 100 kapsula u blisteru, u kutiji [HR-H-879151074-07]; 140 kapsula u blisteru, u kutiji [HR-H-879151074-08]; 196 kapsula u blisteru, u kutiji [HR-H-879151074-09]; 500 kapsula u blisteru, u kutiji [HR-H-879151074-10] Urbroj: 381-12-01/30-16-04

Druge informacije

Status

  • Izvor:
  • HALMED Agencija za lijekove i medicinske proizvode - Agency for medicinal products and medical devices of Croatia
  • Broj odobrenja:
  • HR-H-879151074
  • Datum autorizacije:
  • 22-03-2016
  • Zadnje ažuriranje:
  • 04-06-2018

Uputu o lijeku

Uputa o lijeku: Informacije za bolesnika

Onelar 30 mg tvrde želučanootporne kapsule

duloksetin (u obliku klorida)

Pažljivo pročitajte cijelu uputu prije nego počnete uzimati ovaj lijek jer sadrži Vama važne

podatke.

- Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.

- Ako imate dodatnih pitanja, obratite se svom liječniku ili ljekarniku.

- Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im naškoditi, čak i ako su

njihovi znakovi bolesti jednaki Vašima.

- Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika. To uključuje i

svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4.

Što se nalazi u ovoj uputi:

1. Što je Onelar i za što se koristi?

2. Što morate znati prije nego počnete uzimati Onelar?

3. Kako uzimati Onelar?

4. Moguće nuspojave

5. Kako čuvati Onelar?

6. Sadržaj pakiranja i druge informacije

1.

Što je Onelar i za što se koristi?

Onelar sadrži djelatnu tvar duloksetin. Onelar povećava razine serotonina i noradrenalina u živčanom

sustavu.

Onelar se primjenjuje u odraslih za liječenje:

depresije

generaliziranog anksioznog poremećaja (kroničnog osjećaja tjeskobe ili nervoze)

boli kod dijabetičke neuropatije (često se opisuje kao goruća, probadajuća, žareća, sijevajuća

ili tupa bol ili kao bol nalik elektrošoku. Moguć je gubitak osjeta u zahvaćenom području ili

osjeti poput dodira, topline, hladnoće ili pritiska mogu izazvati bol).

U većine osoba s depresijom ili tjeskobom Onelar počinje djelovati unutar dva tjedna nakon početka

liječenja, ali može biti potrebno 2-4 tjedna prije nego što se počnete osjećati bolje. Obavijestite svoga

liječnika ako se nakon toga razdoblja ne počnete osjećati bolje. Liječnik Vam može nastaviti

propisivati Onelar i nakon što se počnete osjećati bolje, kako bi se spriječio povratak depresije ili

tjeskobe.

H A L M E D

22-03-2016

O D O B R E N O

Osobama koje pate od boli kod dijabetičke neuropatije može biti potrebno nekoliko tjedana prije nego

što se počnu osjećati bolje. Obratite se svom liječniku ako se ne budete osjećali bolje nakon 2

mjeseca.

2.

Što morate znati prije nego počnete uzimati Onelar?

NEMOJTE uzimati Onelar ako:

ste alergični na duloksetin ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6.)

imate bolest jetre

imate tešku bolest bubrega

uzimate ili ste unutar zadnjih 14 dana uzimali drugi lijek koji je poznat kao inhibitor

monoaminooksidaze (MAOI) (vidjeti ‘Drugi lijekovi i Onelar‘)

uzimate fluvoksamin koji se obično koristi za liječenje depresije, ciprofloksacin ili enoksacin

koji se koriste za liječenje nekih infekcija

ako uzimate druge lijekove koji sadrže duloksetin (pogledajte ‘Drugi lijekovi i Onelar’).

Obratite se svom liječniku ako imate visok krvni tlak ili srčanu bolest . Liječnik će Vam reći smijete li

uzimati Onelar.

Upozorenja i mjere opreza

U nastavku su navedeni razlozi zbog kojih Onelar možda nije prikladan lijek za Vas. Obratite se svom

liječniku prije nego uzmete Onelar ako:

uzimate druge lijekove za liječenje depresije (pogledajte ‘Drugi lijekovi i Onelar’)

uzimate gospinu travu, biljni pripravak (

Hypericum perforatum

imate bolest bubrega

ste imali napadaje (konvulzije)

ste imali maniju

patite od bipolarnog poremećaja

imate tegobe s očima poput određenih vrsta glaukoma (povišen očni tlak)

u povijesti bolesti imate poremećaje krvarenja (sklonost pojavi modrica)

imate rizik od pojave niskih razina natrija (na primjer, ako uzimate diuretike, osobito ako ste

starija osoba)

se trenutačno liječite nekim drugim lijekom koji može izazvati oštećenje jetre

uzimate druge lijekove koji sadrže duloksetin (pogledajte ‘Drugi lijekovi i Onelar’).

Onelar može izazvati osjećaj nemira ili nemogućnost mirnog sjedenja ili stajanja. Obavijestite svoga

liječnika ako se to dogodi Vama.

Samoubilačke misli i pogoršanje depresije ili anksioznog poremećaja

depresivni

i/ili

imate

anksiozni

poremećaj,

ponekad

mogu

javiti

misli

H A L M E D

22-03-2016

O D O B R E N O

samoozljeđivanju ili samoubojstvu. To može biti pojačano kada prvi puta započinjete liječenje

antidepresivima jer je svim tim lijekovima potrebno neko vrijeme da počnu djelovati, obično oko dva

tjedna, a ponekad i dulje.

Veća je vjerojatnost da će Vam se pojaviti takve misli ako:

ste prethodno razmišljali o samoubojstvu ili samoozljeđivanju

ste mlađa odrasla osoba. Podaci iz kliničkih ispitivanja pokazale su povećan rizik od

samoubilačkog ponašanja u odraslih koji su mlađi od 25 godina, a zbog psihijatrijskih stanja

su liječeni antidepresivima.

Ako u bilo kojem trenutku pomislite na samoozljeđivanje ili samoubojstvo, odmah se javite

svom liječniku ili idite u bolnicu.

Može Vam koristiti ako kažete članu obitelji ili bliskom prijatelju da ste depresivni ili imate anksiozni

poremećaj i zamolite ih da pročitaju ovu uputu. Mogli biste ih zamoliti da Vam kažu ako smatraju da

se Vaša depresija ili tjeskoba pogoršavaju ili ako su zabrinuti zbog promjena u Vašem ponašanju.

Djeca i adolescenti mlađi od 18 godina

Onelar se u načelu ne smije primjenjivati u djece i adolescenata mlađih od 18 godina. Također,

morate znati da bolesnici mlađi od 18 godina koji se liječe ovom skupinom lijekova imaju povećan

rizik od pojave nuspojava poput pokušaja samoubojstva, misli o samoubojstvu i neprijateljskog

ponašanja (prvenstveno agresivnost, protivljenje i bijes). Ipak, Vaš liječnik može propisati Onelar

bolesnicima mlađima od 18 godina ako procijeni da je to u njihovu najboljem interesu. Ako je liječnik

propisao Onelar bolesniku mlađem od 18 godina i želite o tome razgovarati, vratite se svom liječniku.

Morate obavijestiti liječnika ako se pojavi ili pogorša bilo koji od gore navedenih simptoma kad

bolesnik mlađi od 18 godina uzima Onelar. Nadalje, dugoročni sigurnosni učinci Onelara na rast,

sazrijevanje te intelektualni razvoj i razvoj ponašanja nisu još dokazani u ovoj dobnoj skupini.

Drugi lijekovi i Onelar

Obavijestite svog liječnika ili ljekarnika ako uzimate, ste nedavno uzeli ili biste mogli uzeti bilo koje

druge lijekove.

Duloksetin, glavni sastojak Onelar 30 mg kapsula, nalazi se i u nekim drugim lijekovima koji se

koriste za liječenje drugih stanja:

bol kod dijabetičke neuropatije, depresije, tjeskobe i inkontinencije mokraće

Morate izbjegavati istodobno uzimanje više od jednog takvog lijeka. Provjerite sa svojim liječnikom

uzimate li već neke druge lijekove koji sadrže duloksetin.

Vaš liječnik mora donijeti odluku o tome smijete li uzimati Onelar 30 mg kapsule s drugim

lijekovima.

Nemojte početi ili prestati uzimati bilo koji lijek, uključujući i one koje ste nabavili

bez recepta i biljne pripravke, prije nego što to provjerite sa svojim liječnikom.

H A L M E D

22-03-2016

O D O B R E N O

Morate također reći liječniku ako uzimate i neki od sljedećih lijekova:

Inhibitore monoaminooksidaze (MAOI):

Ne smijete uzimati Onelar ako uzimate ili ste nedavno

(unutar zadnjih 14 dana) uzimali neki drugi antidepresiv koji se naziva inhibitor monoaminooksidaze

(MAOI). Primjeri MAOI-a uključuju moklobemid (antidepresiv) i linezolid (antibiotik). Uzimanje

MAOI-a zajedno s mnogim lijekovima koji se izdaju na recept, uključujući Onelar, može izazvati

ozbiljne, čak i po život opasne nuspojave. Nakon što ste prestali uzimati MAOI,morate pričekati

najmanje 14 dana prije nego počnete uzimati Onelar. Također, nakon što ste prestali uzimati Onelar,

morate pričekati najmanje 5 dana prije nego počnete uzimati MAOI.

Lijekovi koji izazivaju pospanost:

Tu se ubrajaju lijekovi koje Vam je propisao liječnik, uključujući

benzodiazepine, jake lijekove protiv boli, antipsihotike, fenobarbital i antihistaminike.

Lijekovi

koji

povećavaju

razinu

serotonina:

Triptani,

tramadol,

triptofan,

selektivni

inhibitori

ponovne pohrane serotonina (poput paroksetina i fluoksetina), inhibitori ponovne pohrane serotonina i

noradrenalina

(poput

venlafaksina),

triciklički

antidepresivi

(poput

klomipramina,

amitriptilina),

petidin,

gospina

trava

inhibitori

(poput

moklobemida

linezolida).

Navedeni

lijekovi

povećavaju rizik od nuspojava; ako primijetite bilo koji neuobičajen simptom dok uzimate neki od

ovih lijekova zajedno s Onelarom, morate se javiti svom liječniku.

Oralne antikoagulanse ili antitrombocitne lijekove:

Lijekovi koji razrjeđuju krv ili sprječavaju

zgrušavanje krvi. Ti lijekovi mogu povećati rizik od krvarenja.

Onelar s hranom, pićem i alkoholom

Onelar se može uzimati s hranom ili bez nje. Budite posebno oprezni ako pijete alkohol dok uzimate

Onelar.

Trudnoća i dojenje

Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom

liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.

Obavijestite svog liječnika ako zatrudnite ili pokušavate zatrudnjeti dok uzimate Onelar.

Smijete uzimati Onelar tek nakon što razgovarate s liječnikom o mogućim koristima i

mogućim rizicima za nerođeno dijete.

Budite sigurni da primalja i/ili liječnik znaju da uzimate Onelar. Kada se uzimaju tijekom

trudnoće, slični lijekovi (selektivni inhibitori ponovne pohrane serotonina) mogu povećati

rizik od nastanka ozbiljnog stanja za dijete, zvanog trajna plućna hipertenzija novorođenčeta

(PPHN), zbog koje dijete ubrzano diše i koža mu izgleda modra. Ti simptomi obično

H A L M E D

22-03-2016

O D O B R E N O

nastupaju tijekom prva 24 sata nakon djetetova rođenja. Ako se to dogodi Vašem djetetu,

odmah se javite primalji i/ili liječniku.

Ako uzimate Onelar pred kraj trudnoće, Vaše dijete može imati neke simptome kada se rodi.

Oni se obično javljaju pri porodu ili unutar nekoliko dana od rođenja djeteta. Ovi simptomi

mogu

uključivati

mlohave

mišiće,

drhtanje,

nervozne

pokrete,

poteškoće

hranjenjem,

poteškoće s disanjem i napadaje. Ako Vaše dijete ima bilo koji od ovih simptoma kada se

rodi, ili ste zabrinuti zbog djetetova zdravlja, obratite se liječniku ili primalji koji Vas mogu

savjetovati.

Obavijestite svog liječnika ako dojite. Ne preporučuje se uzimanje Onelara za vrijeme dojenja.

Obratite se svom liječniku ili ljekarniku za savjet.

Upravljanje vozilima i strojevima

Onelar može izazvati pospanost ili omaglicu. Nemojte voziti niti rukovati alatima ili strojevima dok

ne vidite kako će Onelar utjecati na Vas.

Onelar sadrži saharozu i karmoizin

Onelar sadrži saharozu. Ako Vam je liječnik rekao da ne podnosite neke šećere, savjetujte se s njime

prije uzimanja ovog lijeka.

Karmoizin može uzrokovati alergijske reakcije.

3.

Kako uzimati Onelar?

Uvijek uzmite ovaj lijek točno onako kako Vam je rekao Vaš liječnik ili ljekarnik. Provjerite s Vašim

liječnikom ili ljekarnikom ako niste sigurni.

Onelar se uzima kroz usta. Kapsulu morate progutati cijelu s vodom.

Za depresiju i bol kod dijabetičke neuropatije:

Uobičajena doza Onelara je 60 mg jednom na dan, no liječnik će Vam propisati dozu

koja Vama najbolje odgovara.

Za generalizirani anksiozni poremećaj:

Uobičajena početna doza Onelara je 30 mg jednom na dan, nakon čega će većina

bolesnika primati 60 mg jednom na dan, no liječnik će propisati dozu koja Vama najbolje odgovara.

Doza se može povisiti do 120 mg na dan, ovisno o Vašem odgovoru na Onelar.

H A L M E D

22-03-2016

O D O B R E N O

Možda ćete se lakše sjetiti uzeti Onelar ako ga svakog dana budete uzimali u isto vrijeme.

Razgovarajte s liječnikom o tome koliko dugo trebate uzimati Onelar. Nemojte prestati uzimati

Onelar niti mijenjati dozu lijeka bez prethodnog razgovora sa svojim liječnikom. Važno je na pravilan

način liječiti Vaše stanje kako biste se osjećali bolje. Ako se ne liječi, bolest se možda neće povući, a

može postati još ozbiljnija i teža za liječenje.

Ako uzmete više Onelara nego što ste trebali

Ako ste uzeli veću količinu Onelara nego Vam je liječnik propisao, odmah nazovite svog liječnika ili

ljekarnika. Simptomi predoziranja uključuju pospanost, komu, serotoninski sindrom (rijetka reakcija

koja može izazvati osjećaj velike sreće, omamljenost, nespretnost, nemir, osjećaj opijenosti, vrućicu,

znojenje ili ukočenost mišića), napadaje, povraćanje i ubrzan rad srca.

Ako ste zaboravili uzeti Onelar

Ako propustite uzeti dozu lijeka, uzmite je čim se sjetite. Međutim, ako je već vrijeme za sljedeću

dozu, preskočite propuštenu dozu i uzmite samo jednu dozu kao inače. Nemojte uzeti dvostruku dozu

kako biste nadoknadili zaboravljenu dozu. Nemojte u jednome danu uzeti više od propisane dnevne

doze Onelara.

Ako prestanete uzimati Onelar

NEMOJTE prestati uzimati kapsule bez prethodnog savjetovanja sa svojim liječnikom, čak i ako se

osjećate bolje. Ako liječnik smatra da više ne trebate Onelar, uputit će Vas da dozu postupno

smanjujete tijekom najmanje 2 tjedna prije nego što potpuno prestanete uzimati lijek.

Neki bolesnici koji su naglo prestali uzimati Onelar imali su simptome kao što su:

omaglica, osjećaj trnaca poput bockanja i iglica ili osjeti nalik strujnom udaru (osobito u

glavi), poremećaji spavanja (živopisni snovi, noćne more, nemogućnost spavanja), umor,

pospanost,

osjećaj

nemira

uznemirenosti,

osjećaj

tjeskobe,

mučnina

povraćanje,

nevoljno drhtanje (tremor), glavobolja, bol u mišićima, razdražljivost, proljev, prekomjerno

znojenje ili vrtoglavica.

Ti simptomi obično nisu ozbiljni i nestaju unutar nekoliko dana, no imate li simptome koji Vas

zabrinjavaju, obratite se liječniku za savjet.

U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku.

4.

Moguće nuspojave

Kao i svi lijekovi, ovaj lijek može uzrokovati nuspojave iako se one neće razviti kod svakoga. Te su

H A L M E D

22-03-2016

O D O B R E N O

nuspojave obično blage do umjerene i često nestaju nakon nekoliko tjedana.

Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba)

glavobolja, pospanost

mučnina, suha usta

Česte nuspojave (mogu se javiti u najviše 1 na 10 osoba):

gubitak apetita

problemi sa spavanjem, osjećaj uznemirenosti, smanjena seksualna želja, tjeskoba, poteškoće

ili nemogućnost postizanja orgazma, neuobičajeni snovi

omaglica, tromost, nevoljno drhtanje, utrnulost, uključujući obamrlost, bockanje ili trnci na

koži

zamućen vid

zujanje/zvonjava u ušima (doživljaj zvuka u ušima kada nema vanjskog zvuka)

osjećaj lupanja srca u prsnom košu

povišen krvni tlak, crvenilo uz osjećaj vrućine

pojačano zijevanje

zatvor, proljev, bol u trbuhu, povraćanje, žgaravica ili loša probava, vjetrovi

pojačano znojenje, osip (koji svrbi)

bol u mišićima, grč mišića

bolno mokrenje, često mokrenje

otežano postizanje erekcije, promjene u ejakulaciji

padovi (najčešće u starijih osoba), umor

gubitak tjelesne težine

Djeca i adolescenti mlađi od 18 godina koji boluju od depresije i liječe se ovim lijekom na početku su

liječenja izgubili na tjelesnoj težini. Nakon 6 mjeseci liječenja njihova je tjelesna težina porasla i

izjednačila se s tjelesnom težinom djece i adolescenata iste dobi i spola.

Manje česte nuspojave (mogu se javiti u najviše 1 na 100 osoba):

upala grla koja uzrokuje promuklost

samoubilačke misli, tegobe sa spavanjem, škripanje ili stiskanje zubima, dezorijentiranost,

nedostatak motivacije

iznenadni nevoljni trzaji ili grčevi mišića, osjećaj nemira ili nemogućnost mirnog sjedenja ili

stajanja, nervoza, poteškoće s koncentracijom, promjene osjeta okusa, poteškoće pri

kontroliranju

pokreta

npr.

nedostatak

koordinacije

nevoljni

pokreti

mišića,

sindrom

nemirnih nogu, loša kvaliteta sna

H A L M E D

22-03-2016

O D O B R E N O

proširene zjenice (tamno središte oka), problemi s vidom

osjećaj omaglice ili vrtoglavice, bol u uhu

brzi i/ili nepravilni otkucaji srca

nesvjestica, omaglica, ošamućenost ili nesvjestica pri ustajanju, hladni prsti na rukama i/ili

nogama

stezanje u grlu, krvarenje iz nosa

povraćanje

krvi

crna katranasta

stolica

(feces),

gastroenteritis,

podrigivanje,

otežano

gutanje

upala jetre koja može izazvati bol u trbuhu i žutilo kože ili bjeloočnica

noćno znojenje, koprivnjača, hladan znoj, osjetljivost na sunčevu svjetlost, povećana sklonost

nastanku modrica

stezanje mišića, trzanje mišića

otežano

mokrenje

nemogućnost

mokrenja,

otežan

početak

mokrenja,

potreba

mokrenjem tijekom noći, pojačana potreba za mokrenjem, smanjen protok mokraće

nenormalno

vaginalno

krvarenje,

nenormalne

mjesečnice,

uključujući

obilne,

bolne,

neredovite ili produljene mjesečnice, neuobičajeno blage mjesečnice ili izostanak mjesečnice,

bol u testisima ili mošnji

bol u prsnom košu, osjećaj hladnoće, žeđ, drhtanje, osjećaj vrućine, nenormalan hod

porast tjelesne težine

Onelar može uzrokovati nuspojave kojih možda i niste svjesni, poput povišenih

vrijednosti jetrenih enzima ili povišene koncentracije kalija, kreatin fosfokinaze, šećera ili

kolesterola u krvi

Rijetke nuspojave (mogu se javiti u najviše 1 na 1000 osoba)

ozbiljna alergijska reakcija koja uzrokuje otežano disanje ili omaglicu s oticanjem jezika ili

usana, alergijske reakcije

smanjena aktivnost štitnjače koja može izazvati umor ili porast tjelesne težine

dehidracija, niske razine natrija u krvi (uglavnom u starijih ljudi; simptomi mogu uključivati

omaglicu, slabost, zbunjenost, pospanost ili izrazit umor, mučninu ili povraćanje; ozbiljniji

simptomi

nesvjestica,

napadaji

padovi),

sindrom

neprimjerenog

izlučivanja

antidiuretskog hormona (SIADH)

samoubilačko ponašanje, manija (prekomjerna aktivnost, brze misli i

smanjena potreba za

spavanjem), halucinacije, agresivnost i bijes

"serotoninski sindrom" (rijetka reakcija koja može izazvati osjećaj velike sreće, omamljenost,

nespretnost, nemir, osjećaj opijenosti, vrućicu, znojenje ili ukočenost mišića), napadaji

povišen očni tlak (glaukom)

upala usta, svijetlocrvena krv u stolici, neugodan zadah

H A L M E D

22-03-2016

O D O B R E N O

zatajenje jetre, žutilo kože ili bjeloočnica (žutica)

Stevens-Johnsonov sindrom (ozbiljna bolest s mjehurićima na koži, ustima, očima i

genitalijama), teška alergijska reakcija koja izaziva oticanje lica ili grla (angioedem)

stezanje mišića čeljusti

nenormalan miris mokraće

simptomi menopauze, nenormalna proizvodnja mlijeka u muškaraca ili žena

Prijavljivanje nuspojava

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika. Ovo uključuje i

svaku moguću nuspojavu koja nije navedena u ovoj uputi. Nuspojave možete prijaviti izravno putem

nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.

Prijavljivanjem nuspojava možete pridonijeti u procjeni sigurnosti ovog lijeka.

5.

Kako čuvati Onelar?

Ovaj lijek čuvajte izvan pogleda i dohvata djece.

Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju.

Čuvati na temperaturi do 30°C u originalnom pakiranju, radi zaštite od vlage.

Nikada nemojte nikakve lijekove bacati u otpadne vode ili kućni otpad. Pitajte svoga ljekarnika kako

baciti lijekove koje više ne koristite. Ove će mjere pomoći u očuvanju okoliša.

6.

Sadržaj pakiranja i druge informacije

Što Onelar sadrži?

- Djelatna tvar je duloksetin. Svaka kapsula sadrži 30 mg duloksetina (u obliku klorida).

- Drugi sastojci su:

Jezgra granule: šećerne kuglice (saharoza, kukuruzni škrob)

.

Ovojnica granule: hipromeloza 2910/5mPa

s, krospovidon tip A, saharoza, talk,

hipromelozaacetatsukcinat, trietilcitrat (E1505), makrogol 8000, titanijev dioksid.

Ovojnica kapsule: titanijev dioksid (E171), želatina, patent plava V (E131), natrijev laurilsulfat,

karmoizin (E122).

Kako Onelar izgleda i sadržaj pakiranja?

Onelar

plavo/bijela

tvrda

želučanootporna

kapsula.

Svaka

Onelar

kapsula

sadrži

granule

duloksetinklorida s ovojnicom koja ih štiti od želučane kiseline.

Onelar je dostupan u 4 jačine: 20 mg, 30 mg, 40 mg i 60 mg.

PA/Al/PVC-Alu blisteri i transparentni PVC/PE/PVDC-Alu blisteri.

H A L M E D

22-03-2016

O D O B R E N O

Veličine pakiranja: blisteri x 7, 28, 30, 56, 84, 98, 100, 140, 196, 500

Na tržištu se ne moraju nalaziti sve veličine pakiranja.

Nositelj odobrenja za stavljanje lijeka u promet i proizvođač

Medochemie Ltd, 1-10 Constantinoupoleos Street, 3011 Limassol, Cipar

Predstavnik nositelja odobrenja za Republiku Hrvatsku

Medicuspharma d.o.o.

Rokov perivoj 6/a

10000 Zagreb

Tel: 01/4920231

Način i mjesto izdavanja lijeka

Lijek se izdaje na recept, u ljekarni.

Ova uputa je zadnji puta revidirana u 03/2016.

H A L M E D

22-03-2016

O D O B R E N O

7-11-2018

Reactie op berichtgeving over nota Waarborgfonds

Reactie op berichtgeving over nota Waarborgfonds

Op dinsdag 30 oktober heeft minister Bruno Bruins een feitenrelaas rondom het faillissement van de MC Groep naar de Tweede Kamer gestuurd.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

31-10-2018

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft guidance on the scientific requirements for health claims related to muscle function and physical performance, prepared by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), supported by the Working Group on Claims. The draft guidance was endorsed by the Panel for public consultation ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Peer review of the pesticide risk assessment of the active substance dimethoate

Peer review of the pesticide risk assessment of the active substance dimethoate

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Italy and co‐rapporteur Member State Bulgaria for the pesticide active substance dimethoate are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of dimetho...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Published on: Tue, 30 Oct 2018 00:00:00 +0100 In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide an update of the reasoned opinion on the review of existing maximum residue levels (MRLs) for imazalil published on 5 September 2017, taking into account the additional information provided on the toxicity of the metabolites R014821, FK‐772 and FK‐284. EFSA did not derive MRL proposals from the post‐harvest uses reported on citrus fru...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Guidance on the scientific requirements for health claims related to muscle function and physical performance

Guidance on the scientific requirements for health claims related to muscle function and physical performance

Published on: Tue, 30 Oct 2018 00:00:00 +0100 EFSA has asked the Panel on Nutrition, Novel Foods and Food Allergens (NDA) to update the guidance on the scientific requirements for health claims related to physical performance published in 2012. The update takes into account the experience gained by the NDA Panel with the evaluation of additional health claim applications, changes introduced to the general scientific guidance for stakeholders for health claims applications and information collected from ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Peer review of the pesticide risk assessment of the active substance methiocarb

Peer review of the pesticide risk assessment of the active substance methiocarb

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State the United Kingdom and co‐rapporteur Member State Germany for the pesticide active substance methiocarb are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative use...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of a strain of Lactobacillus hilgardii and of Lactobacillus buchneri when used as a technological additive intended to improve ensiling at a proposed application rate of 3.0 x 108 colony forming units (CFU)/kg fresh material. The two bacterial species are considered by EFS...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

P. East Trading Corp. Issues Alert on Undeclared Sulfites In Fruits Du Sud Golden Seedless Raisins

P. East Trading Corp. Issues Alert on Undeclared Sulfites In Fruits Du Sud Golden Seedless Raisins

P. EAST TRADING CORP. of Bronx, NY is recalling Fruits Du Sud Golden Seedless Raisins (Lot No. FDS T499/18) 30 lbs Box, because they contain undeclared SULFITES. People who have a severe sensitivity to sulfites run the risk of serious or life-threatening reactions if they consume these products.

FDA - U.S. Food and Drug Administration

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

25-9-2018

Voluntary Recall on Harris Teeter Low Fat Cookies & Cream Frozen Yogurt Due to Undeclared Peanut Product

Voluntary Recall on Harris Teeter Low Fat Cookies & Cream Frozen Yogurt Due to Undeclared Peanut Product

Harris Teeter is notifying shoppers of a voluntarily recall of Harris Teeter Low Fat Frozen Yogurt Cookies & Cream 1.5 qt laminated cartons, UPC 0 72036 98182 0, with all SELL BY DATES up to 07/30/19 due to undeclared peanut product.

FDA - U.S. Food and Drug Administration

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

31-8-2018

Peer review of the pesticide risk assessment of the active substance cypermethrin

Peer review of the pesticide risk assessment of the active substance cypermethrin

Published on: Thu, 30 Aug 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Belgium and co‐rapporteur Member State Germany for the pesticide active substance cypermethrin are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of cype...

Europe - EFSA - European Food Safety Authority Publications

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

6-8-2018

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling 30 1-lb containers of Pat's Cat Turkey Cat Food and 40 2-lb containers of Ground Lamb Dog Food because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes can cause serious and sometimes fatal infections in animals eating the products.

FDA - U.S. Food and Drug Administration

31-7-2018

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

FDA - U.S. Food and Drug Administration

17-7-2018

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Volgend jaar worden zo’n 650.000 kinderen extra opgeroepen om zich te laten inenten tegen de zeer ernstige infectieziekte meningokokken. Het gaat om kinderen die zijn geboren na 1 januari 2001 en voor mei 2004. Dat laat staatssecretaris Paul Blokhuis (VWS) weten in een brief aan de Tweede Kamer. Reden voor deze maatregel is dat in de afgelopen jaren een stijging te zien is van het aantal mensen dat de infectie meningokokken type W oploopt. Met deze extra vaccinatieronde moet die groei worden ingedamd. He...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2080 (Freeline Therapeutics Ltd)

EU/3/18/2080 (Freeline Therapeutics Ltd)

EU/3/18/2080 (Active substance: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant) - Orphan designation - Commission Decision (2018)7281 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/127/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2079 (Spark Therapeutics Ireland Ltd)

EU/3/18/2079 (Spark Therapeutics Ireland Ltd)

EU/3/18/2079 (Active substance: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII) - Orphan designation - Commission Decision (2018)7280 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/104/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2078 (Sellas Life Sciences Limited)

EU/3/18/2078 (Sellas Life Sciences Limited)

EU/3/18/2078 (Active substance: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG) - Orphan designation - Commission Decision (2018)7279 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/091/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2077 (Worphmed Srl)

EU/3/18/2077 (Worphmed Srl)

EU/3/18/2077 (Active substance: Melatonin) - Orphan designation - Commission Decision (2018)7278 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/077/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2075 (Consorcio Centro de InvestigaciOn BiomEdica en Red M.P.)

EU/3/18/2075 (Consorcio Centro de InvestigaciOn BiomEdica en Red M.P.)

EU/3/18/2075 (Active substance: Gefitinib) - Orphan designation - Commission Decision (2018)7276 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/090/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2074 (PhaRA bvba)

EU/3/18/2074 (PhaRA bvba)

EU/3/18/2074 (Active substance: Avapritinib) - Orphan designation - Commission Decision (2018)7275 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/079/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2073 (Fondazione Telethon)

EU/3/18/2073 (Fondazione Telethon)

EU/3/18/2073 (Active substance: Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA) - Orphan designation - Commission Decision (2018)7274 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/113/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Active substance: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile) - Orphan designation - Commission Decision (2018)7272 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate) - Orphan designation - Commission Decision (2018)7273 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/18

Europe -DG Health and Food Safety

30-9-2018

Roteas (Daiichi Sankyo Europe GmbH)

Roteas (Daiichi Sankyo Europe GmbH)

Roteas (Active substance: edoxaban) - PSUSA - Modification - Commission Decision (2018)5089 of Sun, 30 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10387/201710

Europe -DG Health and Food Safety

17-9-2018

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction.   Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept.

FDA - U.S. Food and Drug Administration

30-8-2018

Steglatro (Merck Sharp and Dohme B.V.)

Steglatro (Merck Sharp and Dohme B.V.)

Steglatro (Active substance: ertugliflozin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5789 of Thu, 30 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4315/T/2

Europe -DG Health and Food Safety

30-8-2018

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (Active substance: influenza vaccine (live attenuated, nasal)) - Centralised - Variation - Commission Decision (2018)5815 of Thu, 30 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2617/II/82

Europe -DG Health and Food Safety

3-8-2018

Scandonest and associated names

Scandonest and associated names

Scandonest and associated names (Active substance: mepivacaine) - Community Referrals - Art 30 - Commission Decision (2018)5380 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-30/1455

Europe -DG Health and Food Safety

1-8-2018

Bridion (Merck Sharp and Dohme B.V.)

Bridion (Merck Sharp and Dohme B.V.)

Bridion (Active substance: sugammadex) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5213 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/885/T/30

Europe -DG Health and Food Safety

30-7-2018

Nityr (Cycle Pharmaceuticals Ltd)

Nityr (Cycle Pharmaceuticals Ltd)

Nityr (Active substance: nitisinone) - Centralised - Authorisation - Commission Decision (2018)5446 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4582

Europe -DG Health and Food Safety

30-7-2018

Esmya (Gedeon Richter Plc.)

Esmya (Gedeon Richter Plc.)

Esmya (Active substance: ulipristal) - Referral - Commission Decision (2018)5101 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2041/A-20

Europe -DG Health and Food Safety

30-7-2018

Aimovig (Novartis Europharm Limited)

Aimovig (Novartis Europharm Limited)

Aimovig (Active substance: erenumab) - Centralised - Authorisation - Commission Decision (2018)5102 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4447

Europe -DG Health and Food Safety

30-7-2018

Besponsa (Pfizer Europe MA EEIG)

Besponsa (Pfizer Europe MA EEIG)

Besponsa (Active substance: inotuzumab ozogamicin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5104 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4119/T/7

Europe -DG Health and Food Safety

30-7-2018

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2

Europe -DG Health and Food Safety

30-7-2018

Invokana (Janssen-Cilag International NV)

Invokana (Janssen-Cilag International NV)

Invokana (Active substance: canagliflozin) - Centralised - Renewal - Commission Decision (2018)5105 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2649/R/37

Europe -DG Health and Food Safety

30-7-2018

NovoEight (Novo Nordisk A/S)

NovoEight (Novo Nordisk A/S)

NovoEight (Active substance: turoctocog alfa) - Centralised - 2-Monthly update - Commission Decision (2018)5093 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2719/II/23

Europe -DG Health and Food Safety

30-7-2018

Hyrimoz (Sandoz GmbH)

Hyrimoz (Sandoz GmbH)

Hyrimoz (Active substance: adalimumab) - Centralised - Authorisation - Commission Decision (2018)5097 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4320

Europe -DG Health and Food Safety

30-7-2018

Halimatoz (Sandoz GmbH)

Halimatoz (Sandoz GmbH)

Halimatoz (Active substance: adalimumab) - Centralised - Authorisation - Commission Decision (2018)5098 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4866

Europe -DG Health and Food Safety

30-7-2018

Rasagiline ratiopharm (Teva B.V.)

Rasagiline ratiopharm (Teva B.V.)

Rasagiline ratiopharm (Active substance: rasagiline) - Centralised - Yearly update - Commission Decision (2018)5108 of Mon, 30 Jul 2018

Europe -DG Health and Food Safety

30-7-2018

Hefiya (Sandoz GmbH)

Hefiya (Sandoz GmbH)

Hefiya (Active substance: adalimumab) - Centralised - Authorisation - Commission Decision (2018)5099 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4865

Europe -DG Health and Food Safety

30-7-2018

Alsitek (AB Science)

Alsitek (AB Science)

Alsitek (Active substance: masitinib) - Refusal of authorisation - Commission Decision (2018)5109 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4398

Europe -DG Health and Food Safety

30-7-2018

UBAC (Laboratorios Hipra, S.A.)

UBAC (Laboratorios Hipra, S.A.)

UBAC (Active substance: Streptococcus uberis vaccine (inactivated)) - Centralised - Authorisation - Commission Decision (2018)5152 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4595

Europe -DG Health and Food Safety

30-7-2018

Apoquel (Zoetis Belgium S.A.)

Apoquel (Zoetis Belgium S.A.)

Apoquel (Active substance: Oclacitinib maleate) - Centralised - Renewal - Commission Decision (2018)5153 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2688/R/13

Europe -DG Health and Food Safety

30-7-2018

Ofev (Boehringer Ingelheim International GmbH)

Ofev (Boehringer Ingelheim International GmbH)

Ofev (Active substance: Nintedanib) - PSUSA - Modification - Commission Decision (2018)5115 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10319/201710

Europe -DG Health and Food Safety

30-7-2018

Ceplene (Noventia Pharma Srl)

Ceplene (Noventia Pharma Srl)

Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36

Europe -DG Health and Food Safety

30-7-2018

Zalmoxis (MolMed S.p.A.)

Zalmoxis (MolMed S.p.A.)

Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Renewal - Commission Decision (2018)5118 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/10

Europe -DG Health and Food Safety

30-7-2018

Trazimera (Pfizer Europe MA EEIG)

Trazimera (Pfizer Europe MA EEIG)

Trazimera (Active substance: trastuzumab) - Centralised - Authorisation - Commission Decision (2018)5095 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4463

Europe -DG Health and Food Safety

30-7-2018

RXULTI (Otsuka Pharmaceutical Europe Ltd)

RXULTI (Otsuka Pharmaceutical Europe Ltd)

RXULTI (Active substance: brexpiprazole) - Centralised - Authorisation - Commission Decision (2018)5088 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3841

Europe -DG Health and Food Safety

24-7-2018

ACV meeting statement, Meeting 8, 30 May 2018

ACV meeting statement, Meeting 8, 30 May 2018

Advisory Committee on Vaccines meeting statement

Therapeutic Goods Administration - Australia

11-7-2018

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Active substance: alendronic acid / colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4511 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1180/T/30

Europe -DG Health and Food Safety

11-7-2018

Tovanor Breezhaler (Novartis Europharm Limited)

Tovanor Breezhaler (Novartis Europharm Limited)

Tovanor Breezhaler (Active substance: glycopyrronium bromide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4526 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2690/T/30

Europe -DG Health and Food Safety

6-7-2018

TGA presentation: National Medicines Symposium, 30 May 2018

TGA presentation: National Medicines Symposium, 30 May 2018

This presentation covers the revised requirements for advertisements for medicines containing Schedule 3 substances

Therapeutic Goods Administration - Australia